[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Elpen Pharmaceutical Co. Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100620073","evaluation-of-the-quality-of-life-in-patients-with-chronic-iron-overload-due-to-hemoglobinopathies-in-greece-100620073",false,"NCT07352878","Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece.","Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece, Who Are Under Treatment With Deferasirox, Based on Standard Clinical Practice.","FEROUSA","Inclusion Criteria:\n\n* 1\\. Adult patients (≥ 18 years). 2. Patients with major beta-thalassemia with iron overload due to frequent blood transfusions (≥7 ml\u002Fkg\u002Fmonth of packed red blood cells).\n\n  3\\. Patients with chronic iron overload due to blood transfusions if deferoxamine therapy is contraindicated or insufficient in the following patient groups:\n  * adult patients with major beta-thalassemia with iron overload due to infrequent blood transfusions (\\\u003C7 ml\u002Fkg\u002Fmonth of packed red blood cells).\n  * adult patients with other types of anemia.\n\n    4\\. Patients with non-transfusion-dependent thalassemia syndromes with chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or insufficient.\n\n    5\\. Patients who were receiving deferasirox before their inclusion in the study (90, 180, 360, 900 mg) and at their inclusion require treatment with deferasirox at least 900 mg, as part of the treatment of chronic iron overload and according to the SPC.\n\n    6\\. Consent and compliance of participants with the treatments and procedures of the study.\n\n    7\\. Patients for whom data from the last six months from the date of inclusion (medical history, concomitant medication) are available to determine the endpoints.\n\nExclusion Criteria:\n\n* 1\\. Patients under 18 years of age. 2. Patients with myelodysplastic syndromes. 3. Patients with a contraindication to taking deferasirox 90, 180, 360, 900 mg according to the drug's SmPC.\n\n  4\\. Patients receiving or expect to receive another chelating agent (e.g. deferoxamine, deferiprone) in addition to deferasirox, during the study.\n\n  5\\. Patients with a history of mental illness, substance abuse, to a degree that may prevent their participation in the study.\n\n  6\\. Patients are participating in another research protocol.","ALL","18 Years","100 Years",{"count":21,"type":22},150,"ESTIMATED","OBSERVATIONAL","This observational clinical study aims to evaluate the HRQoL of thalassemia patients with iron overload in Greece, who are under treatment with deferasirox based on standard clinical practice.",[26,27],"Thalassemia","Iron Overload",[29,30,31],"quality of life","iron overload","treatment satisfaction","NOT_YET_RECRUITING","2026-01-13",{"date":35,"type":36},"2026-01-20","ACTUAL",{"date":38,"type":22},"2026-04-15",{"date":40,"type":22},"2027-12-31",{"name":42,"class":43},"Elpen Pharmaceutical Co. Inc.","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":68,"locationsCount":4},"100589095","administration-of-fingolimod-in-greek-patients-with-multiple-sclerosis-100589095","NCT06949956","Administration of Fingolimod in Greek Patients With Multiple Sclerosis.","Administration of Fingolimod in Greek Patients With Multiple Sclerosis for the Evaluation of the Efficacy and Safety, Based on the Standard Clinical Practice.","FILYRA","Inclusion Criteria:\n\n1. Patients over 18 years of age.\n2. Consent and compliance of participants with the treatments and procedures of the study.\n3. Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) according to the revised McDonald 2017 criteria.\n4. Patients who are receiving fingolimod, according to the drug's Summary of product Characteristics (SmPC).\n5. Patients with available follow-up data for at least 12 months prior to their inclusion in the study, which are sufficient to calculate the annualized relapse rate.\n\nExclusion Criteria:\n\n1. Patients under 18 years of age.\n2. Patients with a contraindication to taking fingolimod according to the drug's Summary of product Characteristics (SmPC).\n3. Patients with a history of mental illness, substance abuse, to a degree that may prevent their participation in the study.\n4. Patients participating in another research protocol.",{"count":53,"type":22},140,"The goal of this observational study is to evaluate the efficacy of fingolimod through the estimation of the annualized relapse rate (ARR) over a period of 2 years.\n\nParticipants who are already taking fingolimod as part of their regular medical care for MS will answer questions about their medical history for the past 1 year and for their status for the next 2 years.",[56],"Relapsing Remitting Multiple Sclerosis",[58,59,60,61],"RRMS","ARR","EDSS","Fingolimod","2025-04-29",{"date":64,"type":36},"2025-05-02",{"date":66,"type":22},"2025-06-01",{"date":40,"type":22},{"name":42,"class":43},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":77,"minAge":18,"maxAge":19,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100556707","real-world-study-in-greek-patients-with-bph-for-disease-control-and-qol-under-fdc-treatment-with-solifenacintamsulosin-100556707","NCT06528613","Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin\u002FTamsulosin.","Real World Study in Greek Patients with BPH for the Evaluation of Disease Control and QoL Under FDC Treatment with Solifenacin\u002Ftamsulosin","KALLIRROI","Inclusion Criteria:\n\n* Male adult patient with moderate to severe symptoms of BPH receiving monotherapy and not responding adequately.\n* Male adult patient with BPH who has fully understood the study procedures and signed an informed consent form.\n\nExclusion Criteria:\n\n\\-","MALE",{"count":79,"type":22},450,"Benign prostatic hyperplasia (BPH) is an age-related progressive condition of the prostate gland that results in an increase in prostate size.\n\nAlthough the \"normal\" prostate in adult men usually has a volume of 15-30 ml, a value above 30 ml is usually considered \"enlarged\". However, the threshold at which a prostate is considered enlarged has not been strictly defined and therefore for many physicians an enlarged prostate is a subjective finding on examination.\n\nBPH can only be defined histologically (increase in the number of epithelial cells and stromal cells), but in clinical practice it is characterized by lower urinary tract symptoms \\[LUTS\\]. The disease leads to increased pressure in the urethra, causing resistance to urine flow, known as Bladder Outlet Obstruction (BOO). This resistance can also lead to changes in bladder function caused by the obstruction, such as overactivity of the bladder detrusor muscle or, conversely, reduced detrusor contractility. BOO can present as LUTS, infections or retention, as well as other conditions.\n\nLUTS can be divided into storage (irritant), obstructive (urinary) and post-urinary symptoms and appear frequently causing intense discomfort, reducing the quality of life. LUTS are traditionally associated with bladder outlet resistance (BOO), most commonly when histologic BPH progresses through benign prostatic enlargement (BPE) to benign prostatic obstruction (BPO).The European Urological Association (EAU) reports that LUTS are a common problem in adult men with a significant impact on quality of life (QoL). Accordingly, he suggests the use of the a1-blocker\u002Fmuscarinic receptor antagonist combination in men with moderate to severe storage symptoms, voiding symptoms and PVR \\\u003C 150 ml, in order to reduce the risk of acute urinary retention and relieve irritants. (storage) symptoms, leading to an improvement in the patient's quality of life. Given the small abundance of data for patients in Greece with BPH, this study will evaluate the fixed combination of solifenacin\u002Ftamsulosin in terms of disease control and improvement of the quality of life of patients with BPH. Before enrolling in the study and before signing the consent form, patients must have already received the drug with solifenacin\u002Ftamsulosin and then they are enrolled in the observational study where the physician applies his\u002Fher standard clinical practice.",[82],"Benign Prostatic Hyperplasia","RECRUITING","2025-03-10",{"date":86,"type":36},"2025-03-12",{"date":88,"type":36},"2024-10-23",{"date":90,"type":22},"2025-09-30",{"name":42,"class":43},6,""]